Physician profile
Jonathan Guinto
NPI 1265925333
$4,449.25
in general payments reported to CMS, 2019-2025
24 companies · $60.50 in 2025
The $60.50 reported for 2025 was less than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $120 · 2022: $1,456 · 2023: $1,296 · 2024: $1,517 · 2025: $60.50.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585 · Education: $288.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.47 |
| Education | $287.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,306.07 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $524.02 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $473.52 | 2022-2025 | Winlevi, Ilumya, Absorica Ld |
| Arcutis Biotherapeutics, INC. | $446.24 | 2023-2024 | Zoryve |
| Janssen Biotech, INC. | $426.40 | 2022-2024 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $208.38 | 2021-2024 | Dupixent |
| Lilly USA, LLC | $176.66 | 2022-2023 | Taltz, Olumiant |
| Leo Pharma INC. | $166.25 | 2022-2025 | Adbry |
| Amgen INC. | $135.66 | 2022-2024 | Otezla |
| Sanofi-Aventis U.S. LLC | $99.00 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $84.78 | 2022-2024 | Sotyktu |
| Almirall LLC | $53.61 | 2023-2024 | Seysara, Klisyri |
| Epi Health, LLC | $50.47 | 2022 | |
| Dermavant Sciences, INC. | $39.50 | 2024 | Vtama |
| Genzyme Corporation | $36.07 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $35.94 | 2023-2024 | Opzelura |
| Biofrontera INC. | $32.55 | 2022-2023 | Xepi, Bf-Rhodoled, Ameluz |
| Galderma Laboratories, L.P. | $30.83 | 2023 | Aklief, Oracea, Twyneo |
| Pfizer INC. | $29.85 | 2022-2024 | |
| Merz North America, INC. | $26.48 | 2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $19.95 | 2023 | Siliq |
| Fidia Pharma USA INC. | $17.53 | 2024 | |
| Journey Medical Corporation | $15.65 | 2022 | |
| Medimetriks Pharmaceuticals, INC. | $13.84 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Guinto listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.